retatrutide nejm 2023 obesity trial ly3437943 just posted the biggest weight-loss numbers ever recorded for a drug — 28.3% (≈70 lb) average in Phase 3, with 45% of people hitting 30%+ loss, territory once reserved for bariatric Incretin triple agonist retatrutide (LY3437943)

Proposals for compounding reform are under consideration in California, Colorado and Kentucky

Phung OJ, Scholle JM, Talwar M, Coleman CI

Glossary CKD Chronic kidney disease CVD Cardiovascular disease FDA Food and Drug Administration GLP-1 Glucagon-like peptide-1 GLP-1s Glucagon-like peptide-1 receptor agonists HF Heart failure MASH Metabolic dysfunction-associated steatohepatitis OA Osteoarthritis OSA Obstructive sleep apnea PAD Peripheral arterial disease SC Subcutaneous T2DM Type 2 diabetes mellitus U.S

As with many things B12 related, we need more and better research on B12 metabolism , on the condition of PA and how to treat it most effectively

Nutrient Density Individuals with obesity are at increased risk of micronutrient deficiencies